Radotinib

Radotinib (IY-5511) is an orally active and BBB-permeable selective tyrosine kinase Bcr-Abl1 inhibitor with an IC50 of 34 nM. Radotinib has anti-prion and anti-tumor activities. Radotinib can inhibit the proliferation, induce cell cycle arrest and apoptosis of tumor cells . Radotinib can be used in the research of cancer such as chronic myeloid leukemia and multiple myeloma, as well as neurodegenerative diseases such as prion diseases[1][2][3].

Product Specifications

CAS Number

[926037-48-1]

Product Name Alternative

IY-5511

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Bcr-Abl; JAK; Prion Protein; STAT

Type

Reference compound

Related Pathways

Apoptosis; Epigenetics; JAK/STAT Signaling; Neuronal Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Infection; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Radotinib.html

Purity

99.19

Solubility

DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(NC1=CC(C(F)(F)F)=CC(N2C=C(C)N=C2)=C1)C3=CC=C(C)C(NC4=NC=CC(C5=NC=CN=C5)=N4)=C3

Molecular Formula

C27H21F3N8O

Molecular Weight

530.50

Precautions

H302, H315, H319, H335

References & Citations

[1]Kim SH, et al. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors. Haematologica. 2014 Jul;99 (7) :1191-6.|[2]Heo SK, et al. Radotinib inhibits multiple myeloma cell proliferation via suppression of STAT3 signaling. PLoS One. 2022 May 3;17 (5) :e0265958.|[3]Choi YG, et al. Radotinib Decreases Prion Propagation and Prolongs Survival Times in Models of Prion Disease. Int J Mol Sci. 2023 Jul 31;24 (15) :12241.